Work

A phase I/II study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients who have progressed on prior anti-PD-1 therapy.

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.15_suppl.tps2670

Authors: Shubham Pant, Imke Mulder, Amishi Yogesh Shah, Pavlos Msaouel, Mehmet Altan, John Weinberg, Alex Stevenson, Funda Meric-Bernstam, Timothy A Yap, Vivek Subbiah, Jordi Rodon Ahnert

Institutions: The University of Texas MD Anderson Cancer Center, 4D Pharma (United Kingdom)

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2946945933

Cites:

Cited by: 6

Related to: 10